Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.

This invention relates to compounds of the general formula:

##STR00001## in which the variable groups are as defined herein, and to their preparation and use.

This invention relates to compounds of the general formula:

##STR00001## in which the variable groups are as defined herein, and to their preparation and use.

The invention provides a method for producing an amidate compound, comprising reacting an imidazolium carboxylic acid salt represented by the following formula (1):

##STR00001##

wherein R.sup.1 to R.sup.5 are as defined in the specification, with a polyisocyanate compound represented by the following formula (2):

##STR00002##

wherein A and x are as defined in the specification, and wherein the produced amidate compound is represented by the following formula (3):

##STR00003##

wherein y, z, A, and R.sup.1 to R.sup.5 are as defined in the specification.

The invention provides a method for producing an amidate compound, comprising reacting an imidazolium carboxylic acid salt represented by the following formula (1):

##STR00001##

wherein R.sup.1 to R.sup.5 are as defined in the specification, with a polyisocyanate compound represented by the following formula (2):

##STR00002##

wherein A and x are as defined in the specification, and wherein the produced amidate compound is represented by the following formula (3):

##STR00003##

wherein y, z, A, and R.sup.1 to R.sup.5 are as defined in the specification.

The present invention provides a blocked polyisocyanate composition comprising a blocked polyisocyanate compound and an amidate compound represented by the following Formula (2):

##STR00001##

wherein B, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, and R.sup.11 are as defined in the specification.

Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.

The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

##STR00001##

The present invention relates in certain aspects to the discovery of novel 2-naphthimidamide compounds that are capable of binding Type II Transmembrane Serine Proteases (TTSPs). In certain embodiments, the compounds of the invention can be used to treat or prevent Influenza A viral infection in a mammal.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.